Expert Opinion on Drug Safety

Papers
(The H4-Index of Expert Opinion on Drug Safety is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Genetic alterations conferring resistance to hedgehog inhibitors in basal cell carcinoma77
The risk of menopausal symptoms in premenopausal breast cancer patients and current pharmacological prevention strategies62
Ibrutinib plus rituximab for the treatment of adult patients with Waldenström’s macroglobulinemia: a safety evaluation61
Assessment of adverse events of the novel antiepileptic drug lamotrigine: a real-world pharmacovigilance study based on FAERS57
Hepatic adverse events with CDK4/6 inhibitors: a systematic review combining meta-analysis and FAERS database51
Impact of baseline glucocorticoids (GCs) on cardiotoxic events and myocardial damage related to immune checkpoint inhibitors: a retrospective clinical research47
A cross-sectional study on substandard and falsified medicines (fake or counterfeit drugs) in UK pharmacies during the COVID-19 pandemic45
Safety assessment of esomeprazole: real-world adverse event signal mining and analysis based on FAERS database42
The role of artificial intelligence in pharmacovigilance for rare diseases41
Drug-associated pancreatic cancer: insights from real-world pharmacovigilance and network pharmacology35
Safety profiles of tetracycline-class drugs: a pharmacovigilance analysis of the FAERS database34
Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review34
Real-world safety profile of riluzole: a systematic analysis of data from the FAERS database and case reports33
Cardiac disorder-related adverse events for aryl hydrocarbon receptor agonists: a safety review31
Biological therapies in infants and children younger than 6 years of age with atopic dermatitis: suitability and practical considerations30
Post-marketing safety of pimavanserin: a real-world pharmacovigilance study based on the FDA adverse event reporting system (FAERS)29
Real-world safety evaluation of brivaracetam: insights from the US FDA Adverse Event Reporting System29
The emerging role of Bruton’s tyrosine kinase inhibition in urticaria management29
Data mining study on adverse events of tirzepatide based on FAERS database28
Lessons learned from COVID-19, H1N1, and routine vaccine pharmacovigilance in the United States: a path to a more robust vaccine safety program27
Seizures associated with antibiotics: a real-world disproportionality analysis of FAERS database26
Safety assessment of brexanolone in the FAERS database: real adverse event analysis and discussion of side effects24
Association between methotrexate-induced Stevens-Johnson syndrome/toxic epidermal necrolysis and furosemide: a real-world disproportionality analysis24
Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines23
0.1149480342865